Related Experiment Video

Updated: May 8, 2026

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
08:41

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

14.1K

ASO Author Reflections: Refining Prognostic Staging in De Novo Metastatic Breast Cancer: Validation, Limitations, and

Christopher D Vetter1, Judy C Boughey2

  • 1Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Annals of Surgical Oncology
|August 23, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.2K

Related Experiment Videos

Last Updated: May 8, 2026

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
08:41

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

14.1K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.5K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Articles linked to this work by shared authors, journal, and citation graph.

Neoadjuvant Dual-Targeted HER2 Therapy and Neoadjuvant Chemo-Immunotherapy is Associated with Improved Nodal pCR and Reduced Axillary Surgery.

Annals of surgical oncology·2026

National Assessment of Adherence to Commission on Cancer Standard 5.8 and its Impact on Nodal Upstaging Rates and Operative Morbidity.

The Annals of thoracic surgery·2026

The daily dose: Early usability of an LLM tool for patient summaries and trial matching in radiation oncology.

Clinical and translational radiation oncology·2026

American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 Guidelines for the Management of Proliferative Lesions With Atypia and Lobular Carcinoma In Situ.

JAMA surgery·2026

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

JAMA oncology·2026

Time Interval Between Neoadjuvant Chemotherapy Completion and Mastectomy is Not Associated with 30-Day Complication Rate.

Annals of surgical oncology·2026

Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes.

Annals of surgical oncology·2026

Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.

Annals of surgical oncology·2026

Correlation of Serum DR-70 Levels with Pathological Stage and Nuclear Grade in Localized Renal Cell Carcinoma.

Annals of surgical oncology·2026

Single-Incision Plus One Robot-Assisted Abdominoperineal Resection Using the Hugo RAS System Through a Planned Stoma Site: A Novel Reduced-Port Robotic Surgery.

Annals of surgical oncology·2026

Robotic versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Cancer After Neoadjuvant Therapy: A Dual-Center Retrospective Study.

Annals of surgical oncology·2026

Robotic Partial Central Hepatectomy with Biliary Resection and R-Y Hepaticojejunostomy for Gallbladder Adenocarcinoma: Technique of Biliary Anastomosis with Hepp-Couinaud Maneuver.

Annals of surgical oncology·2026

ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma.

Frontiers in oncology·2026

Nanoprobe-Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma.

Cancer innovation·2026

Number of examined lymph nodes and overall survival in intrahepatic cholangiocarcinoma: a population-based study suggesting a staging benefit.

Frontiers in oncology·2026

LKB1 promotes lung adenocarcinoma cell senescence by suppressing the O-GlcNAc glycosylation-mediated activation of telomerase.

Frontiers in pharmacology·2026

Lactate metabolism and lactylation in uveal melanoma: from metabolic adaptation to immune regulation.

Frontiers in immunology·2026

Associations between C-reactive protein-triglyceride glucose index and asthma risk among Chinese adults: evidence from the CHARLS cohort and external hospital-based validation.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us